home *** CD-ROM | disk | FTP | other *** search
- Document 0814
- DOCN M94B0814
- TI Correlation between response to acyclovir and foscarnet therapy and in
- vitro susceptibility result for isolates of herpes simplex virus from
- human immunodeficiency virus-infected patients.
- DT 9412
- AU Safrin S; Elbeik T; Phan L; Robinson D; Rush J; Elbaggari A; Mills J;
- Department of Medicine, University of California, San Francisco; 94143.
- SO Antimicrob Agents Chemother. 1994 Jun;38(6):1246-50. Unique Identifier :
- AIDSLINE MED/94379774
- AB In vitro susceptibility testing of herpes simplex virus (HSV) isolates
- will play an increasingly important role in guiding the clinical
- management of immunocompromised hosts who have lesions that are poorly
- responsive to therapy with standard antiviral agents. We assessed the
- correlation between the in vitro susceptibility result using a plaque
- reduction assay in Vero cells and the response to antiviral therapy with
- acyclovir or foscarnet for 243 clinical isolates of HSV collected from
- 115 human immunodeficiency virus-infected patients. The in vitro results
- and clinical responses were highly associated for both acyclovir and
- foscarnet (P < 0.001 and P < 0.001, respectively). The predictive values
- of a susceptible result (50% effective concentrations, < 2 micrograms/ml
- for acyclovir and < 100 micrograms/ml for foscarnet) for complete
- healing of lesions were 62% for acyclovir and 82% for foscarnet; the
- predictive values of a resistant result for failure to heal were 95% for
- acyclovir and 88% for foscarnet. Thus, in vitro testing has clinical
- utility in guiding therapy, although the 1 to 2 weeks required to derive
- a definitive result by the plaque reduction assay is a major limitation.
- DE Acyclovir/*PHARMACOLOGY/THERAPEUTIC USE Female
- Foscarnet/*PHARMACOLOGY/THERAPEUTIC USE Herpes Simplex/*DRUG THERAPY
- Human HIV Infections/*MICROBIOLOGY Male Microbial Sensitivity Tests
- Simplexvirus/*DRUG EFFECTS Support, Non-U.S. Gov't JOURNAL ARTICLE
-
- SOURCE: National Library of Medicine. NOTICE: This material may be
- protected by Copyright Law (Title 17, U.S.Code).
-
-